Inactivation of Akt by arsenic trioxide induces cell death via mitochondrial-mediated apoptotic signaling in SGC-7901 human gastric cancer cells

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1645-1652

  Gao, Yan Hui ^a   Zhang, Hao Peng ^b   Yang, Shu Meng ^c   Yang, Yue ^a   Ma, Yu Yan ^a   Zhang, Xin Yu ^b   Yang, Yan Mei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c LINYI PEOPLE'S HOSPITAL   (China)

Author keywords

Akt; Apoptosis; Arsenic trioxide; Mitochondrial membrane potential

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ARSENIC TRIOXIDE; CASPASE 3; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MTT ASSAY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; OXIDES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84904036485     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.2994     Document Type: Article

References (68)

1. Bertuccio P, Chatenoud L, Levi F, et al: Recent patterns in gastric cancer: a global overview. Int J Cancer 125: 666-673, 2009.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001.
4. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
5. Scartozzi M, Galizia E, Verdecchia L, et al: Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opin Pharmacother 8: 797-808, 2007.
6. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006.
7. Emadi A and Gore SD: Arsenic trioxide - an old drug rediscovered. Blood Rev 24: 191-199, 2010.
8. Douer D and Tallman MS: Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23: 2396-2410, 2005.
9. Chen Z, Chen GQ, Shen ZX, et al: Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol 39 (Suppl 1): S22-S26, 2002.
10. Sekeres MA: New data with arsenic trioxide in leukemias and myelodysplastic syndromes. Clin Lymphoma Myeloma 8 (Suppl 1): S7-S12, 2007.
11. Zheng Y, Zhou M, Ye A, Li Q, Bai Y and Zhang Q: The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells. World J Surg Oncol 8: 31, 2010.
12. Fei M, Lu M, Wang Y, et al: Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med Oncol 26: 178-185, 2009.
13. Chow SK, Chan JY and Fung KP: Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J Cell Biochem 93: 173-187, 2004.
14. Qu GP, Xiu QY, Li B, Liu YA and Zhang LZ: Arsenic trioxide inhibits the growth of human lung cancer cell lines via cell cycle arrest and induction of apoptosis at both normoxia and hypoxia. Toxicol Ind Health 25: 505-515, 2009.
15. Karlsson J, Pietras A, Beckman S, Pettersson HM, Larsson C and Påhlman S: Arsenic trioxide-induced neuroblastoma cell death is accompanied by proteolytic activation of nuclear Bax. Oncogene 26: 6150-6159, 2007.
16. Park WH, Cho YH, Jung CW, et al: Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 300: 230-235, 2003.
17. Kanzawa T, Kondo Y, Ito H, Kondo S and Germano I: Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 63: 2103-2108, 2003.
18. Altman JK, Yoon P, Katsoulidis E, et al: Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J Biol Chem 283: 1992-2001, 2008.
19. Miller WH Jr, Schipper HM, Lee JS, Singer J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res 62: 3893-3903, 2002.
20. Zhou J: Arsenic trioxide: an ancient drug revived. Chin Med J 125: 3556-3560, 2012.
21. Mandegary A, Hosseini R, Ghaffari SH, et al: The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide. Ann Oncol 21: 1884-1890, 2010.
22. Zheng Y, Yamaguchi H, Tian C, et al: Arsenic trioxide (As 2O3) induces apoptosis through activation of Bax in hematopoietic cells. Oncogene 24: 3339-3347, 2005.
23. Scholz C, Richter A, Lehmann M, Schulze-Osthoff K, Dörken B and Daniel PT: Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway. Oncogene 24: 7031-7042, 2005.
24. Li Y, Qu X, Qu J, et al: Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett 284: 208-215, 2009.
25. Han YH, Kim SZ, Kim SH and Park WH: Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Cancer Lett 270: 40-55, 2008.
26. Zhao S, Zhang J, Zhang X, Dong X and Sun X: Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep 35: 421-429, 2008.
27. Jarpe MB, Widmann C, Knall C, et al: Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene 17: 1475-1482, 1998.
28. Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene 22: 8983-8998, 2003.
29. Bader AG, Kang S, Zhao L and Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921-929, 2005.
30. Niedermeier M, Hennessy BT, Knight ZA, et al: Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113: 5549-5557, 2009.
31. Garcia-Echeverria C and Sellers WR: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27: 5511-5526, 2008.
32. Redondo-Muñoz J, Escobar-Díaz E, Hernández Del Cerro M, et al: Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. Clin Cancer Res 16: 4382-4391, 2010.
33. Choi YJ, Park JW, Suh SI, et al: Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt. Int J Oncol 21: 603-610, 2002.
34. Tabellini G, Tazzari PL, Bortul R, et al: Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. Br J Haematol 130: 716-725, 2005.
35. Tabellini G, Cappellini A, Tazzari PL, et al: Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 202: 623-634, 2005.
36. Ramos AM, Fernández C, Amrán D, Sancho P, de Blas E and Aller P: Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 105: 4013-4020, 2005.
37. Dougherty CJ, Kubasiak LA, Prentice H, Andreka P, Bishopric NH and Webster KA: Activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stress. Biochem J 362: 561-571, 2002.
38. Shen ZX, Chen GQ, Ni JH, et al: Use of arsenic trioxide (As 2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
39. Jiang X, Chen C, Zhao W and Zhang Z: Sodium arsenite and arsenic trioxide differently affect the oxidative stress, genotoxicity and apoptosis in A549 cells: an implication for the paradoxical mechanism. Environ Toxicol Pharmacol 36: 891-902, 2013.
40. Liu B, Pan S, Dong X, et al: Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 97: 675-681, 2006.
41. Hoffman E and Mielicki WP: Arsenic trioxide: impact on the growth and differentiation of cancer cells and possible use in cancer therapy. Postepy Hig Med Dosw 67: 817-827, 2013 (In Polish).
42. Xiao YF, Liu SX, Wu DD, Chen X and Ren LF: Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer. World J Gastroenterol 12: 5780-5786, 2006.
43. Shao QS, Ye ZY, Ling ZQ and Ke JJ: Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide. World J Gastroenterol 11: 3451-3456, 2005.
44. Hayashi T, Hideshima T, Akiyama M, et al: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 1: 851-860, 2002.
45. Baj G, Arnulfo A, Deaglio S, et al: Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 73: 61-73, 2002.
46. Wu DD, Xiao YF, Geng Y and Hou J: Antitumor effect and mechanisms of arsenic trioxide on subcutaneously implanted human gastric cancer in nude mice. Cancer Genet Cytogenet 198: 90-96, 2010.
47. Soucy NV, Ihnat MA, Kamat CD, et al: Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol Sci 76: 271-279, 2003.
48. Wu YC, Yen WY and Yih LH: Requirement of a functional spindle checkpoint for arsenite-induced apoptosis. J Cell Biochem 105: 678-687, 2008.
49. Zhao S, Tsuchida T, Kawakami K, Shi C and Kawamoto K: Effect of As 2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. Int J Oncol 21: 49-55, 2002.
50. Zhang X, Jia S, Yang S, Yang Y, Yang T and Yang Y: Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression. J Cell Biochem 113: 3528-3535, 2012.
51. Zhang Y, Cao EH and Qin JF: Up-regulation of telomere-binding TRF1, TRF2 related to reactive oxygen species induced by As2O3 in MGC-803 cells. Eur J Pharmacol 516: 1-9, 2005.
52. Jiang XH, Wong BC, Yuen ST, et al: Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 91: 173-179, 2001.
53. Baysan A, Yel L, Gollapudi S, Su H and Gupta S: Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. Int J Oncol 30: 313-318, 2007.
54. Paul MK, Kumar R and Mukhopadhyay AK: Dithiothreitol abrogates the effect of arsenic trioxide on normal rat liver mitochondria and human hepatocellular carcinoma cells. Toxicol Appl Pharmacol 226: 140-152, 2008.
55. Shen ZY, Shen J, Cai WJ, Hong C and Zheng MH: The alteration of mitochondria is an early event of arsenic trioxide-induced apoptosis in esophageal carcinoma cells. Int J Mol Med 5: 155-158, 2000.
56. Shen ZY, Shen J, Li QS, Chen CY, Chen JY and Yi Z: Morphological and functional changes of mitochondria in apoptotic esophageal carcinoma cells induced by arsenic trioxide. World J Gastroenterol 8: 31-35, 2002.
57. Zhou J, Ye J, Zhao X and Li A: JWA is required for arsenic trioxide induced apoptosis in HeLa and MCF-7 cells via reactive oxygen species and mitochondria linked signal pathway. Toxicol Appl Pharmacol 230: 33-40, 2008.
58. Selvaraj V, Armistead MY, Cohenford M and Murray E: Arsenic trioxide (As2O3) induces apoptosis and necrosis-mediated cell death through mitochondrial membrane potential damage and elevated production of reactive oxygen species in PLHC-1 fish cell line. Chemosphere 90: 1201-1209, 2013.
59. Nutt LK, Gogvadze V, Uthaisang W, Mirnikjoo B, McConkey DJ and Orrenius S: Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis. Cancer Biol Ther 4: 459-467, 2005.
60. Zheng Y, Shi Y, Tian C, et al: Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene 23: 1239-1247, 2004.
61. Uren RT, Dewson G, Chen L, et al: Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. J Cell Biol 177: 277-287, 2007.
62. Chen M, Guerrero AD, Huang L, et al: Caspase-9-induced mitochondrial disruption through cleavage of anti-apoptotic BCL-2 family members. J Biol Chem 282: 33888-33895, 2007.
63. Crowder RJ and Freeman RS: Glycogen synthase kinase-3β activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J Biol Chem 275: 34266-34271, 2000.
64. Szanto A, Bognar Z, Szigeti A, Szabo A, Farkas L and Gallyas F Jr: Critical role of bad phosphorylation by Akt in cytostatic resistance of human bladder cancer cells. Anticancer Res 29: 159-164, 2009.
65. Cardone MH, Roy N, Stennicke HR, et al: Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321, 1998.
66. Chiu HW, Ho SY, Guo HR and Wang YJ: Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/Akt and ERK1/2 signaling pathways. Autophagy 5: 472-483, 2009.
67. Qian W, Liu J, Jin J, Ni W and Xu W: Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leuk Res 31: 329-339, 2007.
68. Mann KK, Colombo M and Miller WH Jr: Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Mol Cancer Ther 7: 1680-1687, 2008.